Scandion Oncology: We adjust our estimates for CORIST part 2 top-line data - Redeye

Redeye adjusts its financial and fair value estimates following Scandion’s conference call on CORIST part 2 top-line data. We judge CORIST part 2 will likely miss its primary efficacy endpoint, and modestly lower our estimated LoA and peak sales estimate for SCO-101. We adjust our fair value estimate accordingly.

Länk till analysen i sin helhet: https://www.redeye.se/research/857043/scandion-oncology-we-adjust-our-estimates-for-corist-part-2-top-line-data?utm_source=finwire&utm_medium=RSS